Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20210714003
TCTR20210714003
Recruiting
Phase 2

Immunogenicity and safety of heterologous prime boost COVID-19 vaccines in Thai people.

Chulabhorn Royal Academy0 sites264 target enrollmentJuly 14, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsThe immune response after heterologous COVID-19 vaccine administration in healthy volunteers.COVID-19 vaccine, heterologous prime-boost, ChAdOx1, coronavac, Sinovac.

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
The immune response after heterologous COVID-19 vaccine administration in healthy volunteers.
Sponsor
Chulabhorn Royal Academy
Enrollment
264
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 14, 2021
End Date
October 5, 2021
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. 18 years old or more 2\. Negative urine pregnancy test (in case of potential of pregnancy) 3\. No history of a severe allergic reaction to the prior vaccine. 4\. No fever nor history of fever within 14 days. 5\. No symptoms of respiratory tract infection within 14 days. 6\. sign informed consent to the study.

Exclusion Criteria

  • •1\. prior COVID\-19 vaccination. 2\. pregnancy. 3\. lactation.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
TRAP VAC TRIAMalariaPaediatrics
PACTR2010020001771828niversity of Oxford30
Completed
Not Applicable
Safety of Malaria vaccines in Gambian infantsMalariaPaediatrics
PACTR201401000363170niversity of Oxford36
Completed
Not Applicable
Safety of Malaria vaccines in Gambian childreMalariaPaediatrics
PACTR201204000362870niversity of Oxford36
Unknown
Not Applicable
Safety of Malaria vaccines in Gambian adults , children and infantsMalaria
PACTR201008000221638Oxford University, Jenner Institute52
Recruiting
Phase 4
Safety and Immunogenicity of heterologous or homologous booster after complete vaccination against COVID-19.Covid19D012141
RBR-5y9y7p7Secretaria Municipal de Saúde do Rio de Janeiro